


**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the Claims:**

What is claimed is:

1. (Original) A compound of Formula (I):



or a salt, solvate, or physiologically functional derivative thereof:

wherein:

D is  $-NRR^1$ ,  $-OR$ ,  $-SR$ ,  $-S(O)R$ , or  $-S(O)_2R$ ;

R is hydrogen,  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_7$  cycloalkyl, aralkyl, aryl, heteroaryl,  $-C(O)NR^1R^1$ ,  $-C(O)OR^1$ , acyl, aroyl, or heteroaroyl;

$R^1$  is hydrogen,  $C_1$ - $C_8$  alkyl,  $C_3$ - $C_7$  cycloalkyl, aralkyl, or aryl;

$R^2$  is  $C_1$ - $C_6$  alkyl or  $C_3$ - $C_7$  cycloalkyl;

$R^3$  is hydrogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, aralkyl, cyanoalkyl,

$-(\text{CH}_2)_p\text{C}=\text{CH}(\text{CH}_2)_t\text{H}$ ,  $-(\text{CH}_2)_p\text{C}\equiv\text{C}(\text{CH}_2)_t\text{H}$ , or  $\text{C}_3\text{-C}_7$  cycloalkyl;

$p$  is 1, 2, or 3;

$t$  is 0 or 1;

$\text{R}^4$  is hydrogen, halo, or cyano;

$\text{Q}_1$  is hydrogen, halo,  $\text{C}_1\text{-C}_2$  haloalkyl,  $\text{C}_1\text{-C}_2$  alkyl,  $\text{C}_1\text{-C}_2$  alkoxy, or  $\text{C}_1\text{-C}_2$  haloalkoxy;

$\text{Q}_2$  is  $\text{A}^1$  or  $\text{A}^2$ ;

$\text{Q}_3$  is  $\text{A}^1$  when  $\text{Q}_2$  is  $\text{A}^2$  and  $\text{Q}_3$  is  $\text{A}^2$  when  $\text{Q}_2$  is  $\text{A}^1$ ;

wherein

$\text{A}^1$  is hydrogen, halo,  $\text{C}_1\text{-C}_3$  alkyl,  $\text{C}_1\text{-C}_3$  haloalkyl,  $-\text{OR}^5$ , and

$\text{A}^2$  is the group defined by  $-(\text{Z})_m-(\text{Z}^1)-(\text{Z}^2)$ , wherein

$\text{Z}$  is  $\text{CH}_2$  and  $m$  is 0, 1, 2, or 3, or

$\text{Z}$  is  $\text{NR}^5$  and  $m$  is 0 or 1, or

$\text{Z}$  is oxygen and  $m$  is 0 or 1, or

$\text{Z}$  is  $\text{CH}_2\text{NR}^6$  and  $m$  is 0 or 1;

$\text{Z}^1$  is  $\text{S}(\text{O})_2$ ,  $\text{S}(\text{O})$ , or  $\text{C}(\text{O})$ ; and

$\text{Z}^2$  is  $\text{C}_1\text{-C}_4$  alkyl, cycloalkyl, heterocyclyl,  $-\text{NR}^8\text{R}^9$ , aryl, arylamino, aralkyl, aralkoxy, or heteroaryl;


$\text{R}^5$  and  $\text{R}^6$  are each independently selected from hydrogen, hydroxyl, alkoxy, aryloxy, aralkoxy,  $\text{C}_1\text{-C}_4$  alkyl,  $\text{C}_3\text{-C}_7$  cycloalkyl, heterocyclyl,  $-\text{S}(\text{O})_2\text{R}^7$ , and  $-\text{C}(\text{O})\text{R}^7$ ;

$\text{R}^7$  is  $\text{C}_1\text{-C}_4$  alkyl, or  $\text{C}_3\text{-C}_7$  cycloalkyl;

$\text{R}^8$  is hydrogen, hydroxyl,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy, aryloxy, aralkoxy,  $\text{C}_3\text{-C}_7$  cycloalkyl, and  $\text{C}_3\text{-C}_7$  cycloalkoxy; and

$\text{R}^9$  is hydrogen,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_3\text{-C}_7$  cycloalkyl, aryl, acyl, carbamoyl, or heterocyclyl.

2. (Original) A compound of Formula (II):



(II)

or a salt, solvate, or physiologically functional derivative thereof:

wherein:

R is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, aralkyl, aryl, heteroaryl, -C(O)NR<sup>1</sup>R<sup>1</sup>, -C(O)OR<sup>1</sup>, acyl, aroyl, or heteroaroyl;

R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, aralkyl, or aryl;

R<sup>2</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>3</sub>-C<sub>7</sub> cycloalkyl;

R<sup>3</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, aralkyl, cyanoalkyl, -(CH<sub>2</sub>)<sub>p</sub>C=CH(CH<sub>2</sub>)<sub>t</sub>H, -(CH<sub>2</sub>)<sub>p</sub>C≡C(CH<sub>2</sub>)<sub>t</sub>H, or C<sub>3</sub>-C<sub>7</sub> cycloalkyl;

p is 1, 2, or 3;

t is 0 or 1;

R<sup>4</sup> is hydrogen, halo, or cyano;

Q<sub>1</sub> is hydrogen, halo, C<sub>1</sub>-C<sub>2</sub> haloalkyl, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub> alkoxy, or C<sub>1</sub>-C<sub>2</sub> haloalkoxy;

Q<sub>2</sub> is A<sup>1</sup> or A<sup>2</sup>;

Q<sub>3</sub> is A<sup>1</sup> when Q<sub>2</sub> is A<sup>2</sup> and Q<sub>3</sub> is A<sup>2</sup> when Q<sub>2</sub> is A<sup>1</sup>;

wherein

A<sup>1</sup> is hydrogen, halo, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> haloalkyl, -OR<sup>5</sup>, and

A<sup>2</sup> is the group defined by -(Z)<sub>m</sub>-(Z<sup>1</sup>)-(Z<sup>2</sup>), wherein

Z is CH<sub>2</sub> and m is 0, 1, 2, or 3, or

Z is NR<sup>5</sup> and m is 0 or 1, or

Z is oxygen and m is 0 or 1, or

Z is CH<sub>2</sub>NR<sup>6</sup> and m is 0 or 1;

Z<sup>1</sup> is S(O)<sub>2</sub>, S(O), or C(O); and

Z<sup>2</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl, cycloalkyl, heterocyclyl, -NR<sup>8</sup>R<sup>9</sup>, aryl, arylamino, aralkyl, aralkoxy, or heteroaryl;

R<sup>5</sup> and R<sup>6</sup> are each independently selected from hydrogen, hydroxyl, alkoxy, aryloxy, aralkoxy, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, heterocyclyl, -S(O)<sub>2</sub>R<sup>7</sup>, or -C(O)R<sup>7</sup>;

R<sup>7</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>3</sub>-C<sub>7</sub> cycloalkyl;

R<sup>8</sup> is hydrogen, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, aryloxy, aralkoxy, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, or C<sub>3</sub>-C<sub>7</sub> cycloalkoxy; and

R<sup>9</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, aryl, acyl, carbamoyl, or heterocyclyl.

3. (Original) A compound as claimed in claim 1, wherein D is -NRR<sup>1</sup>.

4. (Original) A compound as claimed in claim 1, wherein D is -NRR<sup>1</sup> and R is C<sub>1</sub>-C<sub>8</sub> alkyl, aryl, or aralkyl and R<sup>1</sup> is hydrogen.

5. (Original) A compound as claimed in claim 1, wherein D is -NRR<sup>1</sup>, wherein R is methyl, isopropyl, benzyl, or phenyl and R<sup>1</sup> is hydrogen.

6. (Currently Amended) A compound as claimed in claim 1 ~~or 2~~, wherein R<sup>2</sup> is C<sub>1</sub>-C<sub>8</sub> alkyl.

7. (Currently Amended) A compound as claimed in claim 1 ~~or 2~~, wherein R<sup>2</sup> is methyl.

8. (Currently Amended )                      A compound as claimed in claim 1 ~~or~~ 2, wherein ~~in one embodiment,~~  $R^3$  is hydrogen,  $C_1$ - $C_4$  alkyl, cyanoalkyl, or  $-(CH_2)_pC\equiv C(CH_2)_tH$ .
  
9. (Currently Amended)                      A compound as claimed in claim 1 ~~or~~ 2, wherein  $R^3$  is hydrogen, methyl, ethyl, isopropyl, cyanomethyl, or  $-(CH_2)_pC\equiv C(CH_2)_tH$ , wherein p is 1 and t is 0.
  
10. (Currently Amended) A compound as claimed in claim 1 ~~or~~ 2, wherein  $R^3$  is methyl.
  
11. (Currently Amended) A compound as claimed in claim 1 ~~or~~ 2, wherein  $R^4$  is hydrogen or halo.
  
12. (Currently Amended) A compound as claimed in claim 1 ~~or~~ 2, wherein ~~in a preferred embodiment,~~  $R^4$  is hydrogen.
  
13. (Currently Amended) A compound as claimed in claim 1 ~~or~~ 2, wherein  $Q_1$  is hydrogen, halo,  $C_1$ - $C_2$  alkyl or  $C_1$ - $C_2$  alkoxy.
  
14. (Currently Amended) A compound as claimed in claim 1 ~~or~~ 2, wherein  $Q_1$  is hydrogen, chloro, methyl, or methoxy.
  
15. (Currently Amended) A compound as claimed in claim 1 ~~or~~ 2, wherein  $Q_2$  is  $A^1$  and  $Q_3$  is  $A^2$ .
  
16. (Currently Amended) A compound as claimed in claim 1 ~~or~~ 2, wherein  $Q_2$  is  $A^2$  and  $Q_3$  is  $A^1$ .
  
17. (Currently Amended) A compound as claimed in claim 1 ~~or~~ 2, wherein  $Q_2$  is  $A^2$  and  $Q_3$  is  $A^1$ , wherein  $A^1$  is hydrogen, halo, or  $C_1$ - $C_3$  haloalkyl and  $A^2$  is the group defined by  $-(Z)_m-(Z^1)-(Z^2)$ , wherein Z is  $CH_2$  and m is 0 or 1;  $Z^1$  is

$S(O)_2$ ; and  $Z^2$  is  $C_1-C_4$  alkyl or  $NR^8R^9$  and wherein  $R^8$  is hydrogen  $C_1-C_4$ alkyl, or alkoxy and  $R^9$  is hydrogen,  $C_1-C_4$ alkyl, or alkoxy.

18. (Currently Amended) A compound as claimed in claim 1 ~~or~~ 2, wherein  $Q_2$  is  $A^2$  and  $Q_3$  is  $A^1$ , wherein  $A^1$  is hydrogen or chloro and  $A^2$  is the group defined by  $-(Z)_m-(Z^1)-(Z^2)$ , wherein  $Z$  is  $CH_2$  and  $m$  is 0 or 1;  $Z^1$  is  $S(O)_2$ ; and  $Z^2$  is methyl or  $-NH_2$ .

19. (Currently Amended) A compound as claimed in claim 1 ~~or~~ 2, wherein  $Q_2$  is  $A^1$  and  $Q_3$  is  $A^2$ , wherein  $A^1$  is hydrogen, halo, or  $C_1-C_3$  alkyl and  $A^2$  is the group defined by  $-(Z)_m-(Z^1)-(Z^2)$ , wherein  $Z$  is  $CH_2$  and  $m$  is 0 or 1;  $Z^1$  is  $S(O)_2$ ; and  $Z^2$  is  $C_1-C_4$  alkyl or  $NR^8R^9$ , and wherein  $R^8$  is hydrogen  $C_1-C_4$ alkyl, or alkoxy and  $R^9$  is hydrogen,  $C_1-C_4$ alkyl, or alkoxy.

20. (Currently Amended) A compound as claimed in claim 1 ~~or~~ 2, wherein  $Q_2$  is  $A^1$  and  $Q_3$  is  $A^2$ , wherein  $A^1$  is hydrogen, methyl, or chloro and  $A^2$  is the group defined by  $-(Z)_m-(Z^1)-(Z^2)$ , wherein  $Z$  is  $CH_2$  and  $m$  is 0 or 1;  $Z^1$  is  $S(O)_2$ ; and  $Z^2$  is  $NR^8R^9$ , wherein  $R^8$  is methoxy and  $R^9$  is hydrogen.

21. (Original) A compound as claimed in claim 1, wherein  $D$  is  $-NRR^1$ , where  $R$  is  $C_1-C_8$  alkyl, aryl, or aralkyl and  $R^1$  is hydrogen;  $R^2$  is  $C_1-C_8$  alkyl.  $R^2$  is methyl;  $R^3$  is methyl;  $R^4$  is hydrogen;  $Q_1$  is hydrogen, chloro, methyl, or methoxy;  $Q_2$  is  $A^2$  and  $Q_3$  is  $A^1$ , where  $A^1$  is hydrogen or chloro and  $A^2$  is the group defined by  $-(Z)_m-(Z^1)-(Z^2)$ , where  $Z$  is  $CH_2$  and  $m$  is 0 or 1;  $Z^1$  is  $S(O)_2$ ; and  $Z^2$  is methyl or  $-NH_2$ .

22. (Original) A compound as claimed in claim 1, wherein  $D$  is  $-NRR^1$ , where  $R$  is  $C_1-C_8$  alkyl, aryl, or aralkyl and  $R^1$  is hydrogen;  $R^2$  is  $C_1-C_8$  alkyl.  $R^2$  is methyl;  $R^3$  is methyl;  $R^4$  is hydrogen;  $Q_1$  is hydrogen, chloro, methyl, or methoxy;  $Q_2$  is  $A^1$  and  $Q_3$  is  $A^2$ , where  $A^1$  is hydrogen, methyl, or chloro and  $A^2$  is the group defined by  $-(Z)_m-(Z^1)-(Z^2)$ , where  $Z$  is  $CH_2$  and  $m$  is 0 or 1;  $Z^1$  is  $S(O)_2$ ; and  $Z^2$  is  $NR^8R^9$ , where  $R^8$  is methoxy and  $R^9$  is hydrogen.

23. (Original) A compound as claimed in claim 1, selected from the group consisting of:

*N*<sup>2</sup>-isopropyl-*N*<sup>5</sup>,1-dimethyl-*N*<sup>5</sup>-[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]-1*H*-benzimidazole-2,5-diamine;

*N*<sup>2</sup>-isopropyl-*N*<sup>5</sup>,1-dimethyl-*N*<sup>5</sup>-[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]-1*H*-benzimidazole-2,5-diamine;

1-{4-[(4-{methyl[1-methyl-2-(methylamino)-1*H*-benzimidazol-5-yl]amino}pyrimidin-2-yl)amino]phenyl}methanesulfonamide;

*N*<sup>2</sup>-benzyl-*N*<sup>5</sup>,1-dimethyl-*N*<sup>5</sup>-[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]-1*H*-benzimidazole-2,5-diamine;

*N*<sup>5</sup>,1-dimethyl-*N*<sup>5</sup>-[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]-*N*<sup>2</sup>-phenyl-1*H*-benzimidazole-2,5-diamine; and

5-({4-[[2-(benzylamino)-1-methyl-1*H*-benzimidazol-5-yl](methyl)amino]pyrimidin-2-yl}amino)-*N*-methoxy-2-methylbenzenesulfonamide;

or a salt, solvate, or physiologically functional derivative thereof.

24. (Original) A compound as claimed in claim 1, selected from the group:

3-{4-[(2-benzylamino-1-methyl-1*H*-benzimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

5-{4-[(2-benzylamino-1-methyl-1*H*-benzimidazol-5-yl)-methyl-amino]-pyrimidinylamino}-2-methyl-benzenesulfonamide;

(4-{4-[(2-benzylamino-1-methyl-1*H*-benzimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

2-(4-{4-[(2-benzylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-ethanesulfonic acid methylamide;

3-(4-{[2-(4-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

5-(4-{[2-(4-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

$N^2$ -(4-fluoro-benzyl)- $N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

[4-(4-{[2-(4-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

2-[4-(4-{[2-(4-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-ethanesulfonic acid methylamide;

3-(4-{[2-(4-methoxy-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

5-(4-{[2-(4-methoxy-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

$N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^2$ -(4-methoxy-benzyl)-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

[4-(4-{[2-(4-methoxy-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

2-[4-(4-{[2-(4-methoxy-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-ethanesulfonic acid methylamide;

5-(4-([2-(3-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino)-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

3-(4-([2-(3-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino)-pyrimidin-2-ylamino)-benzenesulfonamide;

$N^2$ -(3-fluoro-benzyl)- $N^6$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

[4-(4-([2-(3-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino)-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

2-[4-(4-([2-(3-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino)-pyrimidin-2-ylamino)-phenyl]-ethanesulfonic acid methylamide;

3-(4-([2-(4-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino)-pyrimidin-2-ylamino)-benzenesulfonamide;

5-(4-([2-(4-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino)-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

2-[4-(4-([2-(4-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino)-pyrimidin-2-ylamino)-phenyl]-ethanesulfonic acid methylamide;

$N^2$ -(4-chloro-benzyl)- $N^6$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

3-(4-[(2-benzylamino-1-ethyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino)-benzenesulfonamide;

5-(4-[(2-benzylamino-1-ethyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

$N^2$ -benzyl-1-ethyl- $N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^6$ -methyl-1H-benzoimidazole-2,5-diamine;

(4-{4-[(2-benzylamino-1-ethyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

3-(4-{[2-(2-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylmethyl)-benzenesulfonamide;

5-(4-{[2-(2-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

[4-(4-{[2-(2-fluoro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

2-(4-{4-[(2-benzylamino-1-ethyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-ethanesulfonic acid methylamide;

3-(4-{methyl-[1-methyl-2-(1-phenyl-ethylamino)-1H-benzoimidazol-5-yl]-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

2-methyl-5-(4-{methyl-[1-methyl-2-(1-phenyl-ethylamino)-1H-benzoimidazol-5-yl]-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

$N^6$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1,  $N^6$ -dimethyl- $N^2$ -(1-phenyl-ethyl)-1H-benzoimidazole-2,5-diamine;

[4-(4-{methyl-[1-methyl-2-(1-phenyl-ethylamino)-1H-benzoimidazol-5-yl]-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

3-(4-{[2-(3-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

3-(4-{{2-(3-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl}-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

[4-(4-{{2-(4-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl}-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

methanesulfonic acid-3-(4-{{2-(4-chloro-benzylamino)-1-methyl-1H-benzoimidazol-5-yl}-methyl-amino}-pyrimidin-2-ylamino)-phenyl ester;

$N^5$ -{2-[4-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}- $N^2$ -(4-methoxy-benzyl)-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

$N^5$ -{2-[3-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}- $N^2$ -(4-methoxy-benzyl)-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

$N^5$ -{2-[4-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}- $N^2$ -(4-methoxy-benzyl)-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

$N^5$ -{2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl}- $N^2$ -(4-methoxy-benzyl)-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

$N^2$ -benzyl- $N^5$ -{2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl}-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

$N^5$ -{2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl}-1,  $N^5$ -dimethyl- $N^2$ -(1-phenyl-ethyl)-1H-benzoimidazole-2,5-diamine;

$N^5$ -{2-[3-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1,  $N^5$ -dimethyl- $N^2$ -(1-phenyl-ethyl)-1H-benzoimidazole-2,5-diamine;

$N^5$ -{2-[4-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1,  $N^5$ -dimethyl- $N^2$ -(1-phenyl-ethyl)-1H-benzoimidazole-2,5-diamine;

2-methyl-5-(4-{methyl-[1-methyl-2-(4-methyl-benzylamino)-1H-benzoimidazol-5-yl]-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*<sup>5</sup>-dimethyl-*N*<sup>2</sup>-(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine;

*N*<sup>5</sup>-[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*<sup>5</sup>-dimethyl-*N*<sup>2</sup>-(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine;

*N*<sup>5</sup>-[2-[4-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl]-1, *N*<sup>5</sup>-dimethyl-*N*<sup>2</sup>-(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine;

*N*<sup>5</sup>-[2-[3-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl]-1, *N*<sup>5</sup>-dimethyl-*N*<sup>2</sup>-(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine; and

*N*<sup>5</sup>-[2-[4-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl]-1, *N*<sup>5</sup>-dimethyl-*N*<sup>2</sup>-(4-methyl-benzyl)-1H-benzoimidazole-2,5-diamine;  
or a salt, solvate, or physiologically functional derivative thereof.

25. (Original) A compound as claimed in claim 1, selected from the group:

(1-methyl-5-{methyl-[2-(3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-phenyl-carbamic acid tert-butyl ester;

3-{4-[methyl-(1-methyl-2-phenylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

(1-methyl-5-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-phenyl-carbamic acid tert-butyl ester;

*N*<sup>5</sup>-[2-(3-methanesulfonyl-4-methyl-phenylamino)-pyrimidin-4-yl]-1, *N*<sup>5</sup>-dimethyl-*N*<sup>2</sup>-phenyl-1H-benzoimidazole-2,5-diamine;

*N*<sup>6</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*<sup>6</sup>-dimethyl-*N*<sup>2</sup>-phenyl-1H-benzoimidazole-2,5-diamine;

(4-{4-[methyl-(1-methyl-2-phenylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

methanesulfonic acid 4-{4-[methyl-(1-methyl-2-phenylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-phenyl ester;

3-(4-{[2-(4-fluoro-phenylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

5-(4-{[2-(4-fluoro-phenylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

*N*<sup>2</sup>-(4-fluoro-phenyl)-*N*<sup>6</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*<sup>6</sup>-dimethyl-1H-benzoimidazole-2,5-diamine;

[4-(4-{[2-(4-fluoro-phenylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

methanesulfonic acid 4-(4-{[2-(4-fluoro-phenylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl ester;

methanesulfonic acid 3-(4-{[2-(4-fluoro-phenylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl ester;

*N*<sup>6</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*<sup>6</sup>-dimethyl-*N*<sup>2</sup>-p-tolyl-1H-benzoimidazole-2,5-diamine;

[4-(4-{[2-(4-tert-butyl-phenylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

3-(4-{{2-(4-tert-butyl-phenylamino)-1-methyl-1H-benzoimidazol-5-yl}-methyl-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

5-(4-{{2-(4-tert-butyl-phenylamino)-1-methyl-1H-benzoimidazol-5-yl}-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

$N^2$ -(4-tert-butyl-phenyl)- $N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

(5-{{2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl}-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-(4-methoxy-phenyl)-carbamic acid tert-butyl ester;

$N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^2$ -(4-methoxy-phenyl)-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

(4-methoxy-phenyl)-(1-methyl-5-{methyl-[2-(4-sulfamoylmethyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-carbamic acid tert-butyl ester;

[4-(4-{{2-(4-methoxy-phenylamino)-1-methyl-1H-benzoimidazol-5-yl}-methyl-amino}-pyrimidin-2-ylamino)-phenyl]-methanesulfonamide;

(5-{{2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl}-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-(4-methoxy-phenyl)-carbamic acid tert-butyl ester;

$N^5$ -[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^2$ -(4-methoxy-phenyl)-1,  $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

[5-{{2-[4-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-(4-methoxy-phenyl)-carbamic acid tert-butyl ester;

$N^6$ -{2-[4-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}- $N^2$ -(4-methoxy-phenyl)-1,  $N^6$ -dimethyl-1H-benzoimidazole-2,5-diamine; and

$N^6$ -{2-[3-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}- $N^2$ -(4-methoxy-phenyl)-1,  $N^6$ -dimethyl-1H-benzoimidazole-2,5-diamine;

or a salt, solvate, or physiologically functional derivative thereof.

26. (Original) A compound as claimed in claim 1, selected from the group:

3-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

2-chloro-5-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

5-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-2-methyl-benzenesulfonamide;

2-(4-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-ethanesulfonic acid methylamide;

methanesulfonic acid 4-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl ester;

methanesulfonic acid 3-{4-[(2-isopropylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl ester;

$N^2$ -isopropyl- $N^6$ -[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1,  $N^6$ -dimethyl-1H-benzoimidazole-2,5-diamine;

3-[4-(1-methyl-2-phenethylamino-1H-benzoimidazol-5-ylamino)-pyrimidin-2-ylamino]-benzenesulfonamide;

2-methyl-5-{4-[methyl-(1-methyl-2-phenethylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

(4-{4-[methyl-(1-methyl-2-phenethylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*<sup>5</sup>-dimethyl-*N*<sup>2</sup>-phenethyl-1H-benzoimidazole-2,5-diamine;

2-(4-{4-[methyl-(1-methyl-2-phenethylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-phenyl)-ethanesulfonic acid methylamide;

*N*<sup>2</sup>-tert-Butyl-*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*<sup>5</sup>-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*<sup>2</sup>-cyclohexyl-*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, *N*<sup>5</sup>-dimethyl-1H-benzoimidazole-2,5-diamine;

5-{4-[(2-cyclohexylamino-1-methyl-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-2-methyl-benzenesulfonamide;

*N*<sup>2</sup>-cyclohexyl-*N*<sup>5</sup>-{2-[3-(2-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1, *N*<sup>5</sup>-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*<sup>2</sup>-cyclohexyl-*N*<sup>5</sup>-{2-[4-(2-methanesulfonyl-ethyl)-phenylamino]-pyridin-4-yl}-1, *N*<sup>5</sup>-dimethyl-1H-benzoimidazole-2,5-diamine;

*N*<sup>2</sup>-cyclohexyl-*N*<sup>5</sup>-{2-[4-(1-methanesulfonyl-ethyl)-phenylamino]-pyrimidin-4-yl}-1, *N*<sup>5</sup>-dimethyl-1H-benzoimidazole-2,5-diamine;

2-methyl-5-{4-[methyl-(1-methyl-2-methylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

(4-{4-[methyl-(1-methyl-2-methylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

3-{4-[methyl-(1-methyl-2-methylamino-1H-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

$N^5$ -[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1,  $N^2$ ,  $N^5$ -trimethyl-1H-benzoimidazole-2,5-diamine; and

(4-{4-[(1-ethyl-2-methylamino-1H-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-phenyl)-methanesulfonamide;

or a salt, solvate, or physiologically functional derivative thereof.

27. (Original) A compound as claimed in claim 1, selected from the group:

$N^1$ -methyl- $N^5$ -[2-(4-Methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^5$ -methyl- $N^2$ -(4-trifluoromethyl-phenyl)-1H-benzoimidazole-2,5-diamine;

$N^2$ -(3-chloro-phenyl)- $N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^1$ , $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

$N^2$ -(4-chloro-phenyl)- $N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^1$ , $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

$N^2$ -(2,4-dichloro-phenyl)- $N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^1$ , $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

$N^2$ -(2,5-dichloro-phenyl)- $N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^1$ , $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

$N^2$ -(2-chloro-4-trifluoromethyl-phenyl)- $N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^1$ , $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

$N^2$ -(2-chloro-5-trifluoromethyl-phenyl)- $N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^1$ , $N^5$ -dimethyl-1H-benzoimidazole-2,5-diamine;

$N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]- $N^1$ , $N^5$ -dimethyl- $N^2$ -(4-morpholin-4-yl-phenyl)-1H-benzoimidazole-2,5-diamine;

*N*<sup>2</sup>-(3-fluoro-phenyl)-*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*<sup>1</sup>,*N*<sup>5</sup>-dimethyl-1*H*-benzoimidazole-2,5-diamine;

*N*<sup>2</sup>-(2,4-difluoro-phenyl)-*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*<sup>1</sup>,*N*<sup>5</sup>-dimethyl-1*H*-benzoimidazole-2,5-diamine;

*N*<sup>2</sup>-(2-chloro-4-fluoro-phenyl)-*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*<sup>1</sup>,*N*<sup>5</sup>-dimethyl-1*H*-benzoimidazole-2,5-diamine;

*N*<sup>2</sup>-(4-chloro-2-fluoro-phenyl)-*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*<sup>1</sup>,*N*<sup>5</sup>-dimethyl-1*H*-benzoimidazole-2,5-diamine;

*N*<sup>2</sup>-(2-chloro-5-fluoro-phenyl)-*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*<sup>1</sup>,*N*<sup>5</sup>-dimethyl-1*H*-benzoimidazole-2,5-diamine;

*N*<sup>2</sup>-(2-fluoro-4-methyl-phenyl)-*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*<sup>1</sup>,*N*<sup>5</sup>-dimethyl-1*H*-benzoimidazole-2,5-diamine;

*N*<sup>2</sup>-(2-fluoro-phenyl)-*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*<sup>1</sup>,*N*<sup>5</sup>-dimethyl-1*H*-benzoimidazole-2,5-diamine;

*N*<sup>2</sup>-(2-fluoro-5-trifluoromethyl-phenyl)-*N*<sup>5</sup>-[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-*N*<sup>1</sup>,*N*<sup>5</sup>-dimethyl-1*H*-benzoimidazole-2,5-diamine;

4-{4-[methyl-(1-methyl-2-methylsulfanyl-1*H*-benzoimidazol-5-yl)-amino]-pyrimidin-2-ylamino}-benzene sulfonamide;

4-{4-[(2-methanesulfinyl-1-methyl-1*H*-benzoimidazol-5-yl)-methyl-amino]-pyrimidin-2-ylamino}-benzenesulfonamide;

4-(4-{methyl-[1-methyl-2-(4-trifluoromethyl-phenylamino)-1*H*-benzoimidazol-5-yl]-amino}-pyrimidin-2-ylamino)-benzenesulfonamide;

(methyl-nitro-1*H*-benzoimidazol-2-yl)-(3-trifluoromethyl-phenyl)-amine;

(methyl-nitro-1*H*-benzoimidazol-2-yl)-(3-trifluoromethyl-phenyl)-carbamic acid dimethyl-ethyl ester;

(amino-methyl-1-benzoimidazol-2-yl)-(3-trifluoromethyl-phenyl)-carbamic acid dimethyl-ethyl ester;

[(2-chloro-pyrimidin-4-yl)-methyl-amino]-methyl-1H -benzoimidazol-2-yl)-(3-trifluoromethyl-phenyl) -carbamic acid dimethyl-ethyl ester; and

$N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-  $N^1$ ,  $N^5$ -dimethyl-  $N^2$ -(3-trifluoromethyl-phenyl)-1H-benzoimidazole-2,5-diamine;

or a salt, solvate, or physiologically functional derivative thereof.

28. (Original) A compound as claimed in claim 1, selected from the group:

$N^2$ -(5-tert-butyl-isoxazol-3-yl)- $N^5$  [2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, $N^5$ -dimethyl-1H-methyl-amino -benzoimidazole-2,5-diamine;

$N^2$ -(5-tert-butyl-isoxazol-3-yl)- $N^5$ -[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1-methyl-1H-benzoimidazole-2,5-diamine;

$N^2$ -(5-tert-butyl-isoxazol-3-yl)- $N^5$ --[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1-methyl-1H--benzoimidazole-2,5-diamine;

$N^2$ -(5-tert-butyl-isoxazol-3-yl)- $N^5$ -[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-1, $N^5$ -dimethyl-1-H-benzoimidazole-2,5-diamine;

$N^2$ -(5-tert-butyl-isoxazol-3-yl)- $N^5$ -[2-(3-methanesulfonyl-4-methyl-phenylamino)-pyrimidin-4-yl]-1-methyl-1H-benzoimidazole-2,5-diamine;

5-(4-{[2-(5-tert-butyl-isoxazol-3-ylamino)-1-methyl-1H-benzoimidazol-5-yl]-methyl-amino}-pyrimidin-2-ylamino)-2-methyl-benzenesulfonamide;

$N^2$ -(6-fluoro-4-H benzo[1,3]dioxin-8-ylmethyl)-  $N^5$  -[2-(3-methanesulfonyl-4-methyl-phenylamino)-pyrimidin-4-yl]-1-methyl-1H-benzoimidazole-2,5-diamine; and

$N^2$ -(5-tert-butyl-isoxazol-3-yl)-1-methyl- $N^5$ - {2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl}-1H -benzoimidazole-2,5-diamine;

or a salt, solvate, or physiologically functional derivative thereof.

29. (Original) A compound as claimed in claim 1, selected from the group:

*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)-*N*-phenylurea;

*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)benzamide;

*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)indoline-1-carboxamide;

*N*-(5-tert-butylisoxazol-3-yl)-*N'*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)urea;

*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)-2-phenylacetamide;

*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)-1-phenylcyclopropanecarboxamide;

*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)isonicotinamide;

*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)cyclohexanecarboxamide;

2-(benzyloxy)-*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)acetamide;

2-(3-methylisoxazol-5-yl)-*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)acetamide;  
and

3-[(dimethylamino)methyl]-*N*-(1-methyl-5-{methyl[2-({4-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-1H-benzimidazol-2-yl)benzamide;

or a salt, solvate, or physiologically functional derivative thereof.

30. (Original) A compound as claimed in claim 1, selected from the group:

*N*-({[3-(4-methanesulfonylmethyl-phenylamino)-phenyl]-methyl-amino}-methyl-1H-benzimidazol-2-yl)-C-thiophen-2-yl-acetamide;

C-fluoro-*N*-({[3-(3-methanesulfonylmethyl-phenylamino)-phenyl]-methyl-amino}-methyl-1H-benzimidazol-2-yl)-trifluoromethyl-benzamide;

difluoro-*N*-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzimidazol-2-yl)-benzamide;

*N*-([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-3,5-bis-trifluoromethyl-benzamide;

cyclohexanecarboxylic acid ([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-amide;

*N*-([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-methyl-benzamide;

*N*-([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-4-methoxy-benzamide;

C-(chloro-trifluoromethyl-phenyl)-*N*-([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

(3,5-bis-trifluoromethyl-phenyl)-*N*-([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

*N*-(5-([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-1-methyl-1H-benzoimidazol-2-yl)-2-(3-trifluoromethylsulfanyl-phenyl)-acetamide;

(2,4-bis-trifluoromethyl-phenyl)-*N*-([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

(2-fluoro-5-trifluoromethyl-phenyl)-*N*-([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

3H-benzotriazole-5-carboxylic acid ([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-amide;

3H-benzoimidazole-5-carboxylic acid ([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-amide;

thiophene-2-carboxylic acid ([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-amide;

thiophene-3-carboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

*N*-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-C-thiophen-2-yl-acetamide;

3-methyl-thiophene-2-carboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

furan-3-carboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

3-methyl-furan-2-carboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

*N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-2-(3-methyl-isoxazol-5-yl)-acetamide;

C-(chloro-trifluoromethyl-phenyl)-*N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

*N*-(5-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-2-(3-trifluoromethylsulfanyl-phenyl)-acetamide;

C-(fluoro-trifluoromethyl-phenyl)-*N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

*N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-dimethyl-butyramide;

2-propyl-pentanoic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

*N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-isobutyramide;

cyclopropanecarboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

*N*-({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-4-methoxy-benzamide;

4-methoxy-*N*-(methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-benzamide;

furan-2-carboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

*N*-(methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-C-thiophen-2-yl-acetamide;

C-(chloro-trifluoromethyl-phenyl)-*N*-(methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-acetamide;

4-methoxy-*N*-[methyl-(methyl-{2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-benzamide;

*N*-[methyl-(methyl-{2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-C-thiophen-2-yl-acetamide;

thiophene-2-carboxylic acid [methyl-(methyl-{2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-amide;

furan-2-carboxylic acid [methyl-(methyl-{2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-amide;

*N*-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-2-(3-methyl-isoxazol-5-yl)-acetamide;

furan-2-carboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

2-(3-methyl-isoxazol-5-yl)-*N*-[methyl-(methyl-{2-[3-(morpholine-4-sulfonyl)-phenylamino]-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-acetamide;

3-methyl-furan-2-carboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

*N*-[methyl-(methyl-{2-[3-(4-methyl-piperazine-1-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-C-thiophen-2-yl-acetamide;

thiophene-2-carboxylic acid [methyl-(methyl-{2-[3-(4-methyl-piperazine-1-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-amide;

furan-2-carboxylic acid [methyl-(methyl-{2-[3-(4-methyl-piperazine-1-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-amide;

2-(3-methyl-isoxazol-5-yl)-*N*-[methyl-(methyl-{2-[3-(4-methyl-piperazine-1-sulfonyl)-phenylamino]-pyrimidin-4-yl}-amino)-1H-benzoimidazol-2-yl]-acetamide;

*N*-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-dimethyl-butyramide;

*N*-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-propionamide;

pentanoic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

*N*-({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-butyramide;

phenyl- *N* -({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H -benzoimidazol-2-yl)-acetamide;

phenylcyclopropanecarboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

1-(2,5-difluoro-phenyl)-cyclopropanecarboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H -benzoimidazol-2-yl)-amide;

1-(4-chloro-phenyl)-cyclopropanecarboxylic acid ({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin -4-yl]-methyl-amino}-methyl-1H -benzoimidazol-2-yl)-amide;

2-(4-fluoro-phenyl)- *N* -({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H -benzoimidazol-2-yl)-acetamide;

(3,5-bistrifluoromethyl-phenyl)- *N* -({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1 H -benzoimidazol-2-yl)-acetamide;

(3,4-dichlorophenyl)- *N* -({[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1 H -benzoimidazol-2-yl)-acetamide;

1-(2,5-difluorophenyl)-cyclopropanecarboxylic acid ({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-amide;

(2,5-difluorophenyl)- *N* -({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

(3,4-dichlorophenyl)- *N* -({[2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H -benzoimidazol-2-yl)-acetamide;

1-(2,5-difluorophenyl)-cyclopropanecarboxylic acid ({[2-(5-ethanesulfonyl-2-methoxy-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H -benzoimidazol-2-yl)-amide;

(2,5-difluorophenyl)- *N* -({[2-(5-ethanesulfonyl-2-methoxy-phenylamino)-pyrimidin-4-yl]-methyl-amino }-methyl-1H -benzoimidazol-2-yl)-acetamide;

1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid ({[2-(5-ethanesulfonyl-2-methoxy-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H -benzoimidazol-2-yl)-amide;

3,4-dichlorophenyl- *N* -({[2-(5-ethanesulfoyl-2-methoxy-phenylamino)-pyrimidin-4-yl]-methyl-amino}-methyl-1H-benzoimidazol-2-yl)-acetamide;

1-(2,5-difluorophenyl)-cyclopropanecarboxylic acid (methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H -benzoimidazol-2-yl)-amide;

1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid (methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H -benzoimidazol-2-yl)-amide;

(3,4-dichlorophenyl)- *N* -(methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H -benzoimidazol-2-yl)-acetamide;

2-(2,3-dimethoxyphenyl)- *N* -(5-{[2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino}-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(2-methoxyphenyl)-*N*-(5-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3-methoxyphenyl)-*N*-(5-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3-methoxyphenyl)-*N*-(5-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(2-fluorophenyl)- *N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3-fluorophenyl)- *N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

(2,5-difluorophenyl)- *N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

(2,3-difluorophenyl)- *N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3,4-dimethoxyphenyl)- *N*-(5-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

(2,5-difluorophenyl)- *N*-(methyl-{methyl-[2-(4-methyl-3-sulfamoyl-phenylamino)-pyrimidin-4-yl]-amino}-1H-benzoimidazol-2-yl)-acetamide;

1-(3,4-dichloro-phenyl)-cyclopropanecarboxylic acid ([2-(3-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-amide;

2-(2-chlorophenyl)- *N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3-chlorophenyl)- *N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(4-chlorophenyl)- *N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(3,5-dimethoxyphenyl)- *N*-(5-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

2-(2,5-dimethoxyphenyl)- *N*-(5-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-1-methyl-1H-benzoimidazol-2-yl)-acetamide;

(2,5-dichlorophenyl)- *N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

*N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-methyl-C-phenyl-butyramide;

(3,5-dimethylphenyl)- *N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

*N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)- phenyl-isobutyramide; and

benzo[1,3]dioxol-5-yl-*N*-([2-(4-methanesulfonylmethyl-phenylamino)-pyrimidin-4-yl]-methyl-amino)-methyl-1H-benzoimidazol-2-yl)-acetamide;

or a salt, solvate, or physiologically functional derivative thereof.

31. (Currently Amended) A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in ~~any one of~~ claims 1 to 30, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

32. (Original) The pharmaceutical composition of claim 31, further comprising at least one additional anti-neoplastic agent.

33. (Original) The pharmaceutical composition of claim 31, further comprising an additional agent which inhibits angiogenesis.

34. (Currently Amended) A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate TIE-2 and VEGFR-2 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in ~~any one of~~ claims 1 to 30, or a salt, solvate, or a physiologically functional derivative thereof.

35. (Original)           The method of claim 34, wherein the disorder is cancer.
36. (Cancelled)
37. (Cancelled)
38. (Cancelled)
39. (Currently Amended) A method of treating cancer in a mammal, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in ~~any one of claims 1 to 30~~, or a salt, solvate, or a physiologically functional derivative thereof.
40. (Original)           The method of claim 39, further comprising administering a therapeutically effective amount of at least one additional anti-cancer therapy.
41. (Currently Amended) The method of claim 40, wherein the additional anti-cancer therapy is administered concomitantly with the administration of the compound, salt, solvate or physiologically functional derivative as claimed in ~~any one of claims 1 to 30~~.
42. (Currently Amended) The method of claim 40, wherein the additional anti-cancer therapy is administered after the administration of the compound, salt, solvate or physiologically functional derivative as claimed in ~~any one of claims 1 to 30~~.
43. (Currently Amended) The method of claim 40, wherein the additional anti-cancer therapy is administered before the administration of the compound, salt, solvate or physiologically functional derivative as claimed in ~~any one of claims 1 to 30~~.

44. (Currently Amended) A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate TIE-2 and VEGFR-2 activity, comprising: administering to said mammal therapeutically effective amounts of (i) a compound as claimed in ~~any one of claims 1 to 30~~, or a salt, solvate or physiologically functional derivative thereof and (ii) an agent to inhibit growth factor receptor function.

45. (Original) The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of platelet derived growth factor receptor.

46. (Original) The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of epidermal growth factor receptor.

47. (Original) The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of the erbB2 receptor.

48. (Original) The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of a VEGF receptor.

49. (Original) The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of the TIE-2 receptor.

50. (Original) The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of the epidermal growth factor receptor and erbB2.

51. (Original) The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of at least two of the epidermal growth factor receptor, erbB2, and erbB4.

52. (Original) The method of claim 44, wherein the agent to inhibit growth factor receptor function inhibits the function of the VEGF receptor and the TIE-2 receptor.

53. (Original) The method of claim 44, wherein the disorder is cancer.

54. (Currently Amended) A method of treating a disorder in a mammal, said disorder being characterized by inappropriate angiogenesis, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in ~~any one of claims 1 to 30~~, or a salt, solvate or physiologically functional derivative thereof.

55. (Original) The method of claim 54, wherein the inappropriate angiogenesis results from at least one of inappropriate VEGFR1, VEGFR2, VEGFR3 or TIE-2 activity.

56. (Original) The method of claim 54, wherein the inappropriate angiogenesis results from inappropriate VEGFR2 and TIE-2 activity.

57. (Original) The method of claim 54, further comprising administering a therapeutically effective amount of a VEGFR2 inhibitor.

58. (Currently Amended) The method of claim 54, wherein the compound as claimed in ~~any one of claims 1 to 17~~ inhibits TIE-2 and VEGFR-2 activity.

59. (Original) The method of claim 54, wherein the disorder is cancer.

60. (Cancelled)